MARKET

ALNY

ALNY

Alnylam Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

187.40
+0.45
+0.24%
After Hours: 187.40 0 0.00% 17:35 09/24 EDT
OPEN
185.90
PREV CLOSE
186.95
HIGH
189.08
LOW
185.40
VOLUME
228.29K
TURNOVER
--
52 WEEK HIGH
209.73
52 WEEK LOW
119.29
MARKET CAP
22.27B
P/E (TTM)
-24.6628
1D
5D
1M
3M
1Y
5Y
Alnylam (ALNY) Files MAA to EMA for Rare Disease Drug Vutrisiran
Alnylam (ALNY) submits a marketing authorization application to the EMA for vutrisiran to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
Zacks · 09/14 13:18
BRIEF-Alnylam Submits Marketing Authorization Application To The European Medicines Agency For Investigational Vutrisiran
reuters.com · 09/13 11:30
Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Investigational Vutrisiran for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for vutrisiran, an investigational RNAi therapeutic fo...
Business Wire · 09/13 11:00
Alnylam Submits Marketing Authorization Application in the EU for Investigational Vutrisiran as Treatment for Protein Buildup Disfunction
MT Newswires · 09/13 09:29
Alnylam Pharmaceuticals Sponsored Study Titled 'Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program' Posted To ClinicalTrials.gov; Study Is Recruiting
https://clinicaltrials.gov/ct2/show/NCT05040373
Benzinga · 09/10 13:37
BRIEF-Alnylam Presents Additional Data From Phase 3 Study Of Amyloidosis Treatment
reuters.com · 09/07 11:36
Alnylam Presents Additional 9-Month Data from HELIOS-A Phase 3 Study of Vutrisiran at the European ATTR (EU-ATTR) Amyloidosis Meeting
CAMBRIDGE, Mass., September 07, 2021--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced additional positive results from subgroup analyses and exploratory endpoints of the HELIOS-A Phase 3 study of vutrisi...
Business Wire · 09/07 11:00
Alnylam Pharmaceuticals Reports Additional Positive Data From Phase 3 Study of Vutrisiran to Treat ATTR Amyloidosis
MT Newswires · 09/07 09:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALNY. Analyze the recent business situations of Alnylam Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 21 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALNY stock price target is 184.16 with a high estimate of 250.00 and a low estimate of 93.00.
EPS
Institutional Holdings
Institutions: 545
Institutional Holdings: 119.94M
% Owned: 100.92%
Shares Outstanding: 118.85M
TypeInstitutionsShares
Increased
138
3.88M
New
57
3.09M
Decreased
126
3.49M
Sold Out
42
315.88K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Executive Director
Michael Bonney
President/Chief Operating Officer
Yvonne Greenstreet
Chief Executive Officer/Director
John Maraganore
Chief Financial Officer/Executive Vice President
Jeffrey Poulton
Corporate Executive
Akshay Vaishnaw
Lead Director/Independent Director
Amy Schulman
Independent Director
Dennis Ausiello
Independent Director
Olivier Brandicourt
Independent Director
Marsha Fanucci
Independent Director
Margaret Hamburg
Independent Director
Steven Paul
Independent Director
David Pyott
Independent Director
Colleen Reitan
Independent Director
Phillip Sharp
No Data
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's commercial products and pipeline of investigational RNAi therapeutics are focused in four Strategic Therapeutic Areas (STArs): Genetic Medicines, Cardio-Metabolic Diseases, Hepatic Infectious Diseases and CNS/Ocular Diseases. The Company's RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). The ONPATTRO (patisiran) is an intravenously administered RNAi therapeutic targeting Transthyretin Amyloidosis (TTR). The GIVLAARI (givosiran) is used to reduce induced liver aminolevulinic acid synthase 1 mRNA, to reduction of toxins associated with attacks and other disease manifestations of Acute Hepatic Porphyria (AHP). The OXLUMO (lumasiran) is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of Primary Hyperoxaluria Type 1 (PH1). The Leqvio (inclisiran) is used for the treatment of adults with hypercholesterolemia.

Webull offers kinds of Alnylam Pharmaceuticals, Inc. stock information, including NASDAQ:ALNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALNY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALNY stock methods without spending real money on the virtual paper trading platform.